18839174

Source:http://linkedlifedata.com/resource/pubmed/id/18839174

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0036525, umls-concept:C0069717, umls-concept:C0123931, umls-concept:C0178602, umls-concept:C0201734, umls-concept:C0205195, umls-concept:C0243095, umls-concept:C0671970, umls-concept:C1522484, umls-concept:C1527249
pubmed:issue	5
pubmed:dateCreated	2009-2-26
pubmed:abstractText	The GONO-FOLFOXIRI regimen demonstrated higher activity and efficacy than FOLFIRI in metastatic colorectal cancer patients. The aim of this study was to determine the maximum tolerated dose of capecitabine, in substitution of 5-fluorouracil, combined with oxaliplatin and irinotecan and to evaluate the pharmacokinetics of the drugs.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7806519
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin, http://linkedlifedata.com/resource/pubmed/chemical/Deoxycytidine, http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil, http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds, http://linkedlifedata.com/resource/pubmed/chemical/capecitabine, http://linkedlifedata.com/resource/pubmed/chemical/irinotecan, http://linkedlifedata.com/resource/pubmed/chemical/oxaliplatin
pubmed:status	MEDLINE
pubmed:month	Apr
pubmed:issn	1432-0843
pubmed:author	pubmed-author:AntonuzzoAA, pubmed-author:BocciGG, pubmed-author:BursiSS, pubmed-author:ChiariKK, pubmed-author:Del TaccaMM, pubmed-author:Di PaoloAA, pubmed-author:FalconeAA, pubmed-author:FornaroLorenzoL, pubmed-author:LoupakisFF, pubmed-author:MasiGG, pubmed-author:PfannerEE, pubmed-author:VasileEE
pubmed:issnType	Electronic
pubmed:volume	63
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	965-9
pubmed:meshHeading	pubmed-meshheading:18839174-Adolescent, pubmed-meshheading:18839174-Adult, pubmed-meshheading:18839174-Aged, pubmed-meshheading:18839174-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:18839174-Bone Neoplasms, pubmed-meshheading:18839174-Camptothecin, pubmed-meshheading:18839174-Colorectal Neoplasms, pubmed-meshheading:18839174-Deoxycytidine, pubmed-meshheading:18839174-Disease-Free Survival, pubmed-meshheading:18839174-Dose-Response Relationship, Drug, pubmed-meshheading:18839174-Feasibility Studies, pubmed-meshheading:18839174-Female, pubmed-meshheading:18839174-Fluorouracil, pubmed-meshheading:18839174-Humans, pubmed-meshheading:18839174-Liver Neoplasms, pubmed-meshheading:18839174-Lung Neoplasms, pubmed-meshheading:18839174-Lymphatic Metastasis, pubmed-meshheading:18839174-Maximum Tolerated Dose, pubmed-meshheading:18839174-Middle Aged, pubmed-meshheading:18839174-Neoplasm Staging, pubmed-meshheading:18839174-Organoplatinum Compounds, pubmed-meshheading:18839174-Pleural Neoplasms, pubmed-meshheading:18839174-Survival Rate, pubmed-meshheading:18839174-Treatment Outcome, pubmed-meshheading:18839174-Young Adult
pubmed:year	2009
pubmed:articleTitle	A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer.
pubmed:affiliation	Department of Oncology, Azienda USL6 of Livorno, Istituto Toscano Tumori, Viale Alfieri, 36, 57124, Livorno, Italy. lorenzo.fornaro@gmail.com
pubmed:publicationType	Journal Article